http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2636943-C2
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_6567176667bebd9f302678c0a710d835 |
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07B2200-13 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/Y02P20-55 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4178 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4184 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D403-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D403-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P1-16 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D403-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D403-04 |
| filingDate | 2013-06-04-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2017-11-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a2e8e5181f2ce5a9264835fb35239f96 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8e72d8c369605e63f1ea0d11a4f7c429 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_da262c29e68f43fae92938c69404974c http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_86054a5fb63a2502e0acbc449e3e4e69 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c03fae56c1a0745296ab5cdc51e19ea4 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8cd4905e4d5151cd696d3c1ca2daf654 |
| publicationDate | 2017-11-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | RU-2636943-C2 |
| titleOfInvention | Anti-viral compound production |
| abstract | FIELD: pharmacology. n SUBSTANCE: invention relates to a process for preparation of a compound of formula I or a pharmaceutically acceptable salt thereof comprising (A) reaction of a combination of formula compound (i) with formula compound (ii) in the presence of a metal catalyst and a base to obtain a compound of formula (iii) or a salt thereof; (B) deprotection of a compound of formula (iii) to obtain a compound of formula (iv) or a salt thereof; (C) bringing the compound of formula (iv) into contact with (S)-2-(methoxycarbonylamino)-3-methylbutanoic acid to obtain a compound of formula I; each PG being independently t-butoxycarbonyl, benzyloxycarbonyl or methoxy or isopropyloxycarbonyl protecting group; Y and Z are independently selected from Br and -B (OR)(OR'), where Y is -B (OR)(OR'), then Z is Br and Y is Br, then Z is - B(OR)(OR'); and R and R' are independently selected from the group consisting of hydrogen and straight or branched C 1-8 -alkyl, or R and R' together represent C 3-8 -cycloalkylene, wherein any alkyl or cycloalkylene is optionally substituted by one or more C 1-6 -alkyl groups. The invention also relates to intermediates and their crystalline forms. n EFFECT: useful for hepatitis treatment. n 26 cl, 2 dwg, 2 ex |
| priorityDate | 2012-06-05-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 212.